Mechanistic view of risk factors for venous thromboembolism - PubMed (original) (raw)
Review
Mechanistic view of risk factors for venous thromboembolism
Pieter H Reitsma et al. Arterioscler Thromb Vasc Biol. 2012 Mar.
Abstract
Venous thromboembolism is an episodic disease with an annual incidence of 2 to 3/1000 per year that is associated with a high morbidity and mortality. Risk factors for venous thromboembolism come in many guises. They fit into an extended version of Virchow's triad and they tilt the hemostatic balance toward clot formation. This can be achieved by decreasing blood flow and lowering oxygen tension, by activating the endothelium, by activating innate or acquired immune responses, by activating blood platelets, or by increasing the number of platelets and red blood cells or modifying the concentrations of pro- and anticoagulant proteins in the blood. In this narrative review we will discuss the known common risk factors within this pathophysiological framework.
Comment in
- Mouse models, risk factors, and treatments of venous thrombosis.
Mackman N. Mackman N. Arterioscler Thromb Vasc Biol. 2012 Mar;32(3):554-5. doi: 10.1161/ATVBAHA.112.246173. Arterioscler Thromb Vasc Biol. 2012. PMID: 22345592 No abstract available.
Similar articles
- Pathophysiology of venous thrombosis.
López JA, Chen J. López JA, et al. Thromb Res. 2009;123 Suppl 4:S30-4. doi: 10.1016/S0049-3848(09)70140-9. Thromb Res. 2009. PMID: 19303501 Review. - Peripheral arterial disease and Virchow's triad.
Bennett PC, Silverman SH, Gill PS, Lip GY. Bennett PC, et al. Thromb Haemost. 2009 Jun;101(6):1032-40. Thromb Haemost. 2009. PMID: 19492144 Review. - Microparticles in vascular disorders: how tissue factor-exposing vesicles contribute to pathology and physiology.
Kleinjan A, Böing AN, Sturk A, Nieuwland R. Kleinjan A, et al. Thromb Res. 2012 Oct;130 Suppl 1:S71-3. doi: 10.1016/j.thromres.2012.08.281. Thromb Res. 2012. PMID: 23026670 Review. - The role of procoagulants and anticoagulants in the development of venous thromboembolism.
Bertina RM. Bertina RM. Thromb Res. 2009;123 Suppl 4:S41-5. doi: 10.1016/S0049-3848(09)70142-2. Thromb Res. 2009. PMID: 19303503 Review. - Role of selectins and fibrinolysis in VTE.
Wakefield TW, Myers DD, Henke PK. Wakefield TW, et al. Thromb Res. 2009;123 Suppl 4:S35-40. doi: 10.1016/S0049-3848(09)70141-0. Thromb Res. 2009. PMID: 19303502 Review.
Cited by
- Venous thromboembolism among physically active young adult females.
Shapiro M, Hamulyák EN, Leader A, Landau R, Middeldorp S, Gurevich-Shapiro A. Shapiro M, et al. Res Pract Thromb Haemost. 2023 Oct 20;7(8):102236. doi: 10.1016/j.rpth.2023.102236. eCollection 2023 Nov. Res Pract Thromb Haemost. 2023. PMID: 38193067 Free PMC article. - Impact of thyroid function on coagulation and venous thromboembolism: a two-sample mendelian randomization study.
Li X, Lin P, Qi M, Zhou H, Liang Z. Li X, et al. J Thromb Thrombolysis. 2024 Oct;57(7):1145-1153. doi: 10.1007/s11239-024-03025-7. Epub 2024 Aug 7. J Thromb Thrombolysis. 2024. PMID: 39110374 - New insights into modulation of thrombin formation.
Spronk HM, Borissoff JI, ten Cate H. Spronk HM, et al. Curr Atheroscler Rep. 2013 Nov;15(11):363. doi: 10.1007/s11883-013-0363-3. Curr Atheroscler Rep. 2013. PMID: 24026641 Review. - Blood Cells and Venous Thromboembolism Risk: A Two-Sample Mendelian Randomization Study.
He J, Jiang Q, Yao Y, Shen Y, Li J, Yang J, Ma R, Zhang N, Liu C. He J, et al. Front Cardiovasc Med. 2022 Jul 8;9:919640. doi: 10.3389/fcvm.2022.919640. eCollection 2022. Front Cardiovasc Med. 2022. PMID: 35872889 Free PMC article. - Optimization of quantitative proteomic analysis of clots generated from plasma of patients with venous thromboembolism.
Stachowicz A, Siudut J, Suski M, Olszanecki R, Korbut R, Undas A, Wiśniewski JR. Stachowicz A, et al. Clin Proteomics. 2017 Nov 28;14:38. doi: 10.1186/s12014-017-9173-x. eCollection 2017. Clin Proteomics. 2017. PMID: 29209155 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources